A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...

Multiple myeloma (MM), the second most common hematologic malignancy in the United States, has undergone transformative ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...

A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...

We are entering an era where "cure," specifically a functional cure, is no longer a forbidden word in the myeloma community.

(NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO ® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

Pfizer reported that its multiple myeloma therapy Elrexfio met the primary goal in a late-stage study, significantly extending progression-free survival for patients who had received at least one ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...